Navigation Links
BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD

A new drug, peramivir, claimed to be a highly potent formulation for combating the virulent forms of the H5N1 bird flu virus has been credited with a fast-track review by the Food and Drug Administration. //

This novel drug, produced by the pharmaceutical company BioCryst can be injected intravenously. Promising results have been obtained from drug trials conducted against different bird flu strains. If successful and approved we could soon have a new form of anti-viral therapy to effectively manage the bird flu threat.

"The FDA's decision supports our belief in the potential of peramivir as an effective therapy for the treatment of influenza, including highly virulent, life-threatening strains like those associated with avian influenza," said BioCryst Chairman and CEO Charles Bugg.

The FDA had approved the launch of human trials to test the efficacy and safety of the intravenous formulation of peramivir, last December. Following approval, it has been planned to initiate phase I clinical trials of the drug within March 2006. The drug would be tested on patients suffering from acute influenza infection.

In addition, developing an intramuscular form of the drug is also under consideration. This is belived to be tested on victims of seasonal bird flu. Both the clinical trials are jointly conducted by the National Institutes of Allergy and Infectious Diseases at the National Institute of Health.

Only those drugs, used for the treatment of severe diseases for which there is an unfulfiled medical need would be granted fast-track status by the FDA. A six month review of the sponsor’s drug by the FDA would also be included in the fast-track package.


'"/>




Page: 1

Related medicine news :

1. Rural Population Enjoys Better Mental Health
2. Once-Diabetic Heart/Kidney/Pancreas Transplant Recipient Enjoys Life (And Eating Again)
3. Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses
4. US Reviews Risks Of Tamiflu After 12 Children Die
5. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
6. FDA Accords Priority Review For Pediatric Crohns Disease Drug
7. The Lancet Calls For Review Of Regulatory Process Of Drug Trials
8. Review of Pramod Mahajans Injuries
9. Vaticans Council Reviews Condom Usage
10. Review of Reversal of Spread of Diseases in Africa
11. Closure of NHS Borders Hospitals to be Reviewed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/30/2017)... (PRWEB) , ... April 30, 2017 , ... PracticeMatch, a ... increase in projected attendance for this year’s physician career fairs, with this year’s RSVPs ... complete schedule for the 2017 calendar year of national physician career fairs is located ...
(Date:4/29/2017)... S.C. (PRWEB) , ... April ... ... Southeast’s leading software and web development company, today announced the launch of ... DonorBridge is a solution combining decades of software innovation and industry expertise ...
(Date:4/29/2017)... ... April 29, 2017 , ... TransDark is a set of dynamic transitions ... the next without having to set a single keyframe in Final Cut Pro ... video production. , TransDark features dynamic transitions that momentarily splits the RGB layers of ...
(Date:4/29/2017)... ... April 29, 2017 , ... Sterling Global Products ... fine retailers selling biodegradable, hanging flushable wipes dispensers and/or 42 count refill packs ... in San Antonio, Texas, operates more than 350 stores throughout Texas and expanding ...
(Date:4/29/2017)... ... April 29, 2017 , ... ... and recognize the positive impact veterinarians have on animal health and welfare as ... Organization for Animal Health (OIE) choose a theme each year and this year ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... Halo Labs announces the launch of a ... called the Horizon at PEGS 2017 in ... analyzes sub visible particulate matter in biopharmaceutical samples to ... early as candidate selection and pre-formulation. Halo ... organization Elion Labs for system validation. "We ...
(Date:4/20/2017)... -- Research and Markets has announced the ... Prospects: Addressing Production Complexities Through Risk Management and Quality ... ... and Market Prospects: Overcoming Production Complexities Through Risk Management ... the current trends in the global biosimilars market, with ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
Breaking Medicine Technology: